“Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Efficacy by Baseline Body Surface Area (BSA) Involvement and Baseline Psoriasis Area and Severity Index (PASI)” (2023) SKIN The Journal of Cutaneous Medicine, 7(6), p. s238. doi:10.25251/skin.7.supp.238.